Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

NCT04268706 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Lymphoma, Adult
Hodgkin Disease Recurrent
Hodgkin Disease Refractory
Hodgkin Disease, Pediatric

Interventions

DRUG: CD30.CAR-T
DRUG: Fludarabine
DRUG: Bendamustine

Sponsor

Tessa Therapeutics